ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
혈소판 감소증 시장 규모는 향후 수년간 강력한 성장이 예상될 전망입니다. 혈소판 감소증의 유병률 증가, 의료비 지출 증가, 치료법의 글로벌 확장, 혈액 질환 발생률 증가, 그리고 고령화 인구 증가 등에 기인한다고 생각됩니다. 주요 동향으로는 신규 트롬보포이에틴 수용체 작동약의 채용, 진단 기술의 향상, 유전자 치료의 진보, 단일클론항체 치료의 진보, 환자 모니터링 기술의 강화, 맞춤형 의료 어프로치, 혁신적 치료를 위한 임상시험의 진행 등을 들 수 있습니다.
자가면역 질환의 유병률 상승은 혈소판 감소증 시장의 성장에 큰 영향을 미치고 있습니다.
자가면역 질환은 면역 체계가 신체의 세포를 잘못 표적으로 삼아 다양한 장기와 시스템에 염증과 손상을 일으킬 때 발생합니다. 경우에 따라 자가면역질환은 면역계가 혈소판을 파괴하거나 골수에서 혈소판의 생산을 손상시키는 혈소판 감소증이라는 상태를 초래합니다. 2024년 11월 Versorgungsatlas.de의 데이터에 따르면 독일에서는 2022년에 630만명 이상의 피보험자는 적어도 하나의 자가면역 질환을 진단받고 있으며, 이러한 질병의 부담이 증가하고 있음을 보여주고 있습니다.
자가면역 질환 증가는 혈소판 감소증을 관리하기 위해 설계된 정맥 내 치료의 진보도 뒷받침하고 있습니다. 2024년 3월에 Argenx SE가 일본의 후생노동성에서 성인의 원발성 면역이상증(ITP)에 대한 정주요법인 VYVGART의 승인을 취득했습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 혈소판 감소증 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 혈소판 감소증 시장 : 성장률 분석
세계의 혈소판 감소증 시장 실적 : 규모와 성장, 2019-2024
세계의 혈소판 감소증 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 혈소판 감소증 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 혈소판 감소증 시장 : 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
특발성 혈소판 감소증
혈전성 혈소판 감소증
약물 유발성 혈소판 감소증
세계의 혈소판 감소증 시장 : 약물에 의해 분석과 예측, 2019-2024, 2024-2029F, 2034F
다나졸
정맥내 면역글로불린
리툭시맙
엘트롬보파그
로미프로스티무
비장 적출술
코르티코스테로이드
기타 약물
세계의 혈소판 감소증 시장 : 투여 경로별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
오랄
비경구
기타 투여 경로
세계의 혈소판 감소증 시장 : 최종 사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
병원
전문 클리닉
홈케어
기타 최종 사용자
세계의 혈소판 감소증 시장 : 특발성 혈소판 감소성 자반병(ITP)유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
급성ITP
만성 ITP
세계의 혈소판 감소증 시장 : 혈전성 혈소판 감소성 자반병(TTP)유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
선천성 TTP(유전성 ADAMTS13 결손증)
획득성 TTP(면역 개재성)
세계의 혈소판 감소증 시장 : 약제 유발성 혈소판 감소증(DITP)의별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
헤파린 유발성 혈소판 감소증(히트)
화학요법 유발성 혈소판 감소증
기타 약 관련 혈소판 감소증
제7장 지역별/국가별 분석
세계의 혈소판 감소증 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
세계의 혈소판 감소증 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
혈소판 감소증 시장 :경쟁 구도
혈소판 감소증 시장 : 기업 프로파일
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
Bayer AG Overview, Products and Services, Strategy and Financial Analysis
Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
Novartis AG Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업 및 혁신 기업
GSK Plc
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Amgen Inc.
Merck & Co. Inc.
Teva Pharmaceutical Industries Ltd.
Swedish Orphan Biovitrum AB
Argenx SE
GC Pharma
Biotest AG
UCB Biopharma
Rigel Pharmaceuticals
Millennium Pharmaceuticals
Keros Therapeutics Inc.
Baxalta
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
혈소판 감소증 시장(2029년) : 새로운 기회를 제공하는 국가
혈소판 감소증 시장(2029년) : 새로운 기회를 제공하는 부문
혈소판 감소증 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
SHW
영문 목차
영문목차
Thrombocytopenia refers to a medical condition characterized by an abnormally low platelet count in the blood, which increases the risk of excessive bleeding. Causes include bone marrow disorders, autoimmune diseases, and certain medications. Symptoms involve easy bruising, prolonged bleeding, and petechiae (small red spots on the skin).
The main types of thrombocytopenia are idiopathic thrombocytopenic, thrombotic thrombocytopenic, and drug-induced thrombocytopenia. Idiopathic thrombocytopenic is a condition where the immune system mistakenly attacks and destroys platelets, which play a crucial role in blood clotting. The key drugs used include danazol, intravenous immune globulin, rituximab, eltrombopag, romiplostim, splenectomy, corticosteroids, and others. The various routes of administration are oral, parenteral, and others and are used by several end users, such as hospitals, specialty clinics, homecare, and others.
The thrombocytopenia market research report is one of a series of new reports from The Business Research Company that provides thrombocytopenia market statistics, including the thrombocytopenia industry's global market size, regional shares, competitors with a thrombocytopenia market share, detailed thrombocytopenia market segments, market trends and opportunities, and any further data you may need to thrive in the thrombocytopenia industry. This thrombocytopenia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The thrombocytopenia market size has grown strongly in recent years. It will grow from $4.38 billion in 2024 to $4.72 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth during the historic period can be attributed to the increasing prevalence of autoimmune disorders, the rise in chronic liver disease incidences, greater healthcare service penetration, expansion of healthcare infrastructure, and increased government support.
The thrombocytopenia market size is expected to see strong growth in the next few years. It will grow to $6.29 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth during the forecast period can be attributed to the rising prevalence of thrombocytopenia, increasing healthcare expenditure, the global expansion of therapies, a higher incidence of blood disorders, and the growing aging population. Key trends include the adoption of novel thrombopoietin receptor agonists, improved diagnostic techniques, advancements in gene therapies, progress in monoclonal antibody treatments, enhanced patient monitoring technologies, personalized medicine approaches, and ongoing clinical trials for innovative therapies.
The rising prevalence of autoimmune diseases is significantly influencing the growth of the thrombocytopenia market. Autoimmune diseases occur when the immune system mistakenly targets the body's own cells, leading to inflammation and damage to various organs and systems. In some cases, autoimmune diseases result in thrombocytopenia, a condition where the immune system destroys platelets or impairs their production in the bone marrow. This is driving the demand for treatments that can effectively address platelet depletion and improve overall patient outcomes. According to data from Versorgungsatlas.de in November 2024, over 6.3 million insured individuals in Germany were diagnosed with at least one autoimmune disease in 2022, demonstrating a growing burden of these conditions. This increase in autoimmune diseases contributes to the expanding thrombocytopenia market.
The rise in autoimmune diseases is also propelling advancements in intravenous therapies designed to manage thrombocytopenia. Intravenous treatments offer rapid relief by improving platelet counts, which is crucial in managing the condition, particularly in severe or chronic cases. These therapies reduce the risk of bleeding and accelerate the response to treatment, addressing the urgent needs of patients. A notable example is Argenx SE's approval from Japan's Ministry of Health, Labor, and Welfare (MHLW) in March 2024 for VYVGART, an intravenous therapy for adults with primary immune thrombocytopenia (ITP). This approval represents an important advancement, offering targeted treatment that provides quick, sustained platelet response for patients with autoimmune diseases.
In December 2024, Keros Therapeutics and Takeda Pharmaceutical Industries Ltd. partnered to develop elritercept, a therapy aimed at addressing thrombocytopenia and other rare diseases related to dysfunctional TGF-B signaling. This collaboration reflects the ongoing efforts to innovate and meet the unmet needs of patients affected by autoimmune-related thrombocytopenia, reinforcing the demand for new, effective treatment options.
Major players in the thrombocytopenia market are Pfizer Inc., Johnson & Johnson, Bayer AG, Sanofi S.A., Novartis AG, GSK Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Swedish Orphan Biovitrum AB, Argenx SE, GC Pharma, Biotest AG, UCB Biopharma, Rigel Pharmaceuticals, Millennium Pharmaceuticals, Keros Therapeutics Inc., and Baxalta.
North America was the largest region in the thrombocytopenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in thrombocytopenia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the thrombocytopenia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The thrombocytopenia market consists of revenues earned by entities by providing services such as blood or platelet transfusions, splenectomy, plasma exchange, monitoring, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The thrombocytopenia market also includes sales of pharmaceutical drugs, diagnostic kits, supportive care products, and research and development products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Thrombocytopenia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on thrombocytopenia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for thrombocytopenia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The thrombocytopenia market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Idiopathic Thrombocytopenic; Thrombotic Thrombocytopenic; Drug-Induced Thrombocytopenia
2) By Drugs: Danazol; Intravenous Immune Globulin; Rituximab; Eltrombopag; Romiplostim; Splenectomy; Corticosteroid; Other Drugs
3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
4) By End User: Hospitals; Specialty Clinics; Homecare; Other End Users
Subsegments:
1) By Idiopathic Thrombocytopenic Purpura (ITP): Acute ITP; Chronic ITP
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Thrombocytopenia Market Characteristics
3. Thrombocytopenia Market Trends And Strategies
4. Thrombocytopenia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Thrombocytopenia Growth Analysis And Strategic Analysis Framework
5.1. Global Thrombocytopenia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Thrombocytopenia Market Growth Rate Analysis
5.4. Global Thrombocytopenia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Thrombocytopenia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Thrombocytopenia Total Addressable Market (TAM)
6. Thrombocytopenia Market Segmentation
6.1. Global Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Idiopathic Thrombocytopenic
Thrombotic Thrombocytopenic
Drug-Induced Thrombocytopenia
6.2. Global Thrombocytopenia Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Danazol
Intravenous Immune Globulin
Rituximab
Eltrombopag
Romiplostim
Splenectomy
Corticosteroid
Other Drugs
6.3. Global Thrombocytopenia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
Other Routes Of Administration
6.4. Global Thrombocytopenia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Homecare
Other End Users
6.5. Global Thrombocytopenia Market, Sub-Segmentation Of Idiopathic Thrombocytopenic Purpura (ITP), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute ITP
Chronic ITP
6.6. Global Thrombocytopenia Market, Sub-Segmentation Of Thrombotic Thrombocytopenic Purpura (TTP), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Congenital TTP (Hereditary ADAMTS13 Deficiency)
Acquired TTP (Immune-Mediated)
6.7. Global Thrombocytopenia Market, Sub-Segmentation Of Drug-Induced Thrombocytopenia (DITP), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Heparin-Induced Thrombocytopenia (HIT)
Chemotherapy-Induced Thrombocytopenia
Other Medication-Related Thrombocytopenia
7. Thrombocytopenia Market Regional And Country Analysis
7.1. Global Thrombocytopenia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Thrombocytopenia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
